| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10620-008-0267-1 |
| P698 | PubMed publication ID | 18463983 |
| P2093 | author name string | Kathleen Cieply | |
| Ramesh K Ramanathan | |||
| Alyssa M Krasinskas | |||
| Saima Sharif | |||
| Douglas Potter | |||
| P2860 | cites work | Prognostic and predictive value of HER2/neu oncogene in breast cancer | Q34954864 |
| Current management of locally advanced pancreatic cancer | Q36304248 | ||
| Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. | Q38455600 | ||
| HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis | Q39754520 | ||
| Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis | Q40823460 | ||
| Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu | Q45174616 | ||
| c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent | Q45178475 | ||
| Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? | Q47906737 | ||
| Amplification of a novel v-erbB-related gene in a human mammary carcinoma | Q48375434 | ||
| Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. | Q54649058 | ||
| Overexpression of HER2/neu in solid tumours: an immunohistochemical survey | Q56441712 | ||
| Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms | Q71048246 | ||
| HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival | Q73204437 | ||
| Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes | Q73810358 | ||
| HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization | Q77624096 | ||
| HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors | Q77626790 | ||
| Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma | Q79273702 | ||
| Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma | Q81073375 | ||
| Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab | Q81151636 | ||
| Protein expression and gene amplification of epidermal growth factor receptor in thymomas | Q81226237 | ||
| Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients | Q81414756 | ||
| Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice | Q81894783 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer | Q28678776 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Cancer statistics, 2006 | Q29615133 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy | Q33675112 | ||
| HER2 as a prognostic factor in breast cancer. | Q34428785 | ||
| A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer | Q34546440 | ||
| Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients | Q34722637 | ||
| Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy | Q34743875 | ||
| Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis | Q34778546 | ||
| P433 | issue | 11 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 3026-3032 | |
| P577 | publication date | 2008-05-08 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma | |
| P478 | volume | 53 |
| Q54734323 | HER-2/neu and topoisomerase-II-alpha expression and genic amplification in pancreatic adenocarcinoma. |
| Q36600002 | Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis |
| Q51075580 | Prognostıc value of increased HER2 expression in cancers of pancreas and biliary tree. |
| Q26859002 | The important molecular markers on chromosome 17 and their clinical impact in breast cancer |
Search more.